Anna Schreyer
About Anna Schreyer
Anna Schreyer EVP of Development Operations
Anna Schreyer currently holds the position of Executive Vice President (EVP) of Development Operations. In this role, she oversees the planning, conduct, and management of clinical trials, ensuring smooth operations and data management. Additionally, her responsibilities include the deployment and compliance of quality systems, crucial for maintaining the high standards required in the pharmaceutical and medical device industries. Schreyer has also been involved in business development functions, contributing to the growth and expansion of her organizations.
Anna Schreyer Education and Expertise
Anna Schreyer earned her undergraduate degree from Boston University. With nearly 20 years of experience, she has amassed expertise in both preclinical and clinical development phases. Her proficiency covers clinical trials planning, conduct, quality system planning, data management, and compliance. Schreyer has specialized in integrating new 3D image analysis methods and workflows, particularly for assessing cardiac safety in drugs and medical devices.
Anna Schreyer Background in Pharmaceutical and Medical Device Industries
Anna Schreyer has a significant background in the pharmaceutical and medical device industries, spanning almost two decades. She has worked on the preclinical and clinical development phases, focusing on the operationalization of novel assessment methods for cardiac safety. Schreyer's career includes extensive involvement in project management, data, and operations, making her a versatile professional in these sectors. Her work initially concentrated on integrating innovative 3D image analysis methods and workflows.
Anna Schreyer Involvement in Start-Up Teams
Anna Schreyer has been a crucial part of core start-up teams at VirtualScopics, iCardiac Technologies, and Qmetrics Technologies. These roles have allowed her to contribute to the foundational operations and development strategies of these companies. Her involvement has been instrumental in establishing and operationalizing new methods and workflows, particularly in assessing cardiac safety for drugs and medical devices. Schreyer's start-up experience highlights her ability to drive innovation and efficiency from the ground up.